Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia |
Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD |
Reach Grants |
2015 |
Massachusetts |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |
Mechanistic and Therapeutic Development of ATM as a Tumor Cell Selective Target for Radiosensitization in H3K27M DMG |
The Regents of the University of Michigan / Meredith Morgan, PhD & Daniel Wahl, MD/PhD |
Reach Grants |
2022 |
Michigan |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Novel Genomic Diagnostics for Intracranial Germ Cell Tumors |
Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD |
Reach Grants |
2021 |
Connecticut |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor |
Baylor College of Medicine / William Decker, PhD |
Reach Grants |
2013 |
Texas |
IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas |
Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD |
Reach Grants |
2021 |
New York |